| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nephros, Inc.$3.58
-0.01 (-0.28%)
Market Cap
38.87 M
EPS
0.07
P/E Ratio
50.07 $
Value Trade
32.17 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.21 M
R&D Expenses
346.00 K
Operating CF
-1.67 M
Total Assets
13.79 M
Total Liabilities
3.09 M
Equity
10.70 M
10.49 %
Week
0.85 %
1 Month
11.18 %
3 Month
-12.9 %
6 Month
-57.53 %
5 Year
-99.68 %
All Time
Cash Data
Cash Position
4.02 M
Monthly Burn
557.00 K
Runway
4.2 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.22 K
52 Week Range
2.66 - 6.42
% held by Insiders
13.37 %
% held by Institutions
48.92 %
Enterprise Value
34.85 M
Total Shares
10.86 M
Short %
0.33 %
Float Shares
5.46 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NEPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NEPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NEPH▼ -0.3%today
Nephros Schedules Second Quarter 2026 Financial Results Conference Call
Nephros, Inc. has announced the scheduling of its second quarter 2026 financial results conference call for August 6, 2026, after market close. Participants can join via domestic and international dialing options. An audio archive will be available post-call, and the company emphasizes its commitment to water safety through innovative filtration solutions.
Read more →NEPHNephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Nephros, Inc. announced its participation in the upcoming virtual conference titled 'Health, Wellness & Longevity' organized by Maxim Group LLC. CEO Robert Banks will present at the event, which aims to discuss innovations in consumer health and wellness. The conference will take place on July 22, 2026, and is accessible to institutional investors.
Read more →NEPHNephros Announces Inclusion in the Russell Microcap® Index
Nephros, Inc. has announced its inclusion in the Russell Microcap® Index, effective June 26, 2026. This membership is expected to enhance the company's visibility and attract new institutional investors, following a year of significant achievements. CEO Robert Banks expressed optimism regarding the potential long-term value for shareholders.
Read more →NEPHNephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Nephros, Inc. will host a virtual investor event titled 'Beyond Filtration: The Nephros Model in Action' on July 16, 2026. The event will highlight the company's approach to redefining water safety and its scalable model beyond filtration. Attendees will gain insights from industry leaders and participate in a Q&A session with Nephros leadership.
Read more →NEPHNephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
Nephros, Inc. has emphasized the effectiveness of its ultrafiltration technology in capturing microplastics and nanoplastics, following the U.S. EPA's decision to classify microplastics as a priority contaminant. The company's filters, designed with small pore sizes, are positioned to meet emerging water quality challenges. This advancement aligns with a shift towards proactive water management solutions.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Financial Results for Quarter Ended
Nephros, Inc. reported financial results for the quarter ending March 31, 2026, highlighting a 7% increase in net revenue to $5.2 million. The company achieved a significant milestone by surpassing $5 million in quarterly revenue for the first time. However, net income fell to $140,000 compared to $558,000 in the previous year, attributed to tariff impacts and rising costs. While management remains optimistic about long-term growth prospects, recent shifts in revenue mix could affect margins in the near term.
Read more →NEPH▼ -7.9%on this news· ran to -23% by day 1
Nephros Announces Fourth Quarter and Record Fiscal Year 2025 Financial Results
Nephros, Inc. reported a strong financial performance for Q4 and fiscal year 2025, achieving a 33% increase in net revenue year-over-year. The company also noted positive net income for the second consecutive year, driven by growth in its product and service offerings. However, challenges such as decreased gross margins and the impact of tariffs were highlighted.
Read more →NEPHNephros Schedules Fourth Quarter 2025 Financial Results Conference Call
Nephros, Inc. has announced the scheduling of its fourth-quarter financial results conference call for March 12, 2026. The call will take place at 4:30 PM ET, following the release of the financial results after market close. Participants can join via domestic and international access numbers, and a replay will be available until March 19, 2026.
Read more →NEPH▲ +9%on this news
Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors
Nephros, Inc. has announced its expansion into the Puerto Rican market, focusing on providing advanced water filtration solutions for various sectors, including healthcare and foodservice. The company aims to address significant unmet needs in waterborne pathogen control, estimating a $10 million market opportunity. Nephros plans to differentiate itself through localized service and language-specific support.
Read more →NEPHNephros Launches the Nephros Water Institute to Lead National Water Safety Education
Nephros, Inc. has launched the Nephros Water Institute to enhance national water safety education. This initiative aims to address critical gaps in understanding water safety risks through structured educational programs. The company has already reached nearly 1,000 professionals and plans to expand its educational efforts with monthly webinars in 2026. Nephros emphasizes the importance of practical information for stakeholders responsible for water safety.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Second Quarter Financial Results Second-Quarter Net Revenue of $4.4 million; Robust Growth Drives 36% Incre
Nephros, Inc. announced strong financial results for the second quarter of 2025, highlighting a 36% increase in net revenue to $4.4 million compared to the same period in 2024. The company reported net income of $237,000, marking its third consecutive quarter of profitability. Both adjusted EBITDA and revenue for the first half of 2025 also saw substantial growth. Nephros credits its success to disciplined execution, innovation, and a robust expansion of its customer base, particularly in its dialysis water segment, which recorded significant sales.
Read more →NEPHNephros Announces Financial Results for Quarter Ended
Nephros, Inc. announced its financial results for Q1 2025, reporting a net revenue of $4.9 million, marking a 38% increase from the same period last year. The company achieved a net income of $558,000, a notable improvement from a net loss of $169,000 in Q1 2024. The CEO highlighted strong performance in both programmatic and emergency response business segments, although he noted potential challenges due to macroeconomic uncertainties and regulatory changes. Overall, the results reflect growing demand and operational success, with optimism for sustained growth.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Ne
Nephros, Inc. released its financial results for Q4 and fiscal year 2024, showing a net revenue of $14.2 million for the year, consistent with the previous year. The fourth quarter saw a 19% increase in net revenue compared to Q4 2023, reaching $3.9 million, and the company achieved its first net income of $349,000 in the quarter. Despite meeting overall revenue expectations, challenges in the emergency response sector were noted, which the company managed to overcome with growth in core programmatic business. The launch of the new HydraGuard Ultrafilter is expected to enhance their market position.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call:201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net
Nephros, Inc. reported its financial results for the fourth quarter and fiscal year 2023, showcasing a significant net revenue increase of 43% from the previous year, totaling $14.2 million. The adjusted EBITDA loss improved notably, reflecting enhanced operational efficiency. However, the company continued to post net losses, with a net loss of $1.6 million for the year. Nephros' CEO expressed optimism regarding the company's positioning in the market due to new water safety guidelines and operational improvements.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Hires Judy Krandel as Chief Financial Officer
Nephros, Inc. has appointed Judy Krandel as its new Chief Financial Officer, effective immediately. Krandel has over 20 years of experience in financial leadership, which includes roles in asset management, investment, and financial oversight. She aims to enhance the company's financial operations and contribute to its growth strategy during a time of increasing revenues and cash flow. Her previous experience includes serving as CFO for several public companies where she focused on growth and capital allocation strategies.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended
Nephros, Inc. reported its financial results for the second quarter ended June 30, 2023, showcasing a net revenue of $3.5 million, reflecting a 24% increase year-over-year. While the company achieved positive cash flow and improved gross margins to 59%, it also recorded a net loss of $0.4 million. The number of Active Customer Sites grew by 6%, indicating growth in customer engagement. Despite these gains, Nephros continues to operate with an Adjusted EBITDA loss, raising concerns about profitability.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces CEO Retirement and Succession Plan Robert Banks to Be Named President and Chief Executive Officer; Andy Astor to R
Nephros, Inc. has announced the retirement of CEO Andy Astor, who will be succeeded by Robert Banks. The transition follows Nephros achieving cash-flow breakeven and strong revenue growth of 40% year-over-year in 2023. Astor will remain with the company as an advisor and interim CFO while a search for a permanent CFO is conducted. The board expresses confidence in Banks' abilities to lead the company forward in a strong market position.
Read more →NEPH▲ +14.1%on this news
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for First Quarter 2023 Net Revenue of $3.7 Million, a 69% Year-Over-Year Increase
Nephros, Inc. announced preliminary revenue results for Q1 2023, reporting $3.7 million, a 69% increase compared to the same period last year. The company highlighted a robust base revenue expected to exceed $3.0 million, attributed to recent investments in its field sales organization. Nephros anticipates break-even cash flows from its water filtration operations and aims to achieve consistent positive cash flows by mid-2023. However, the company acknowledges potential risks associated with future growth and its reliance on third-party suppliers.
Read more →NEPH▼ -6.6%on this news· ran to -19% by day 3
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results Full-Year Net Revenue of $10 Million and Fourth Quarter Net
Nephros, Inc. announced its financial results for the fourth quarter and fiscal year 2022, reporting a year-end net revenue of $10 million, a 2% decline from 2021. The fourth quarter alone generated $2.6 million, down 6% from the same quarter a year prior. Despite the decrease in revenue and an increased net loss of $4.3 million for the year, the company has taken strategic steps to aim for cash flow breakeven by mid-2023. Notable improvements include a restructuring of its sales team and increased gross margins.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022 Fourth Quarter Net Revenue of $2.6 Million; Full-Year
Nephros, Inc. announced preliminary revenue results for the fourth quarter and fiscal year 2022, indicating a fourth-quarter net revenue of approximately $2.6 million, a slight increase from the previous quarter but a decrease from the same quarter last year. The full-year net revenue is expected to be around $10 million, reflecting a 2% decline from 2021. Despite these challenges, the company reported a record number of active customer sites and a significant improvement in cash flow during the latter half of the year. Their fourth quarter results will be formally released on March 8, 2023.
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Preliminary Results for Quarter Ended
Announces Agreement to Sell Pathogen Detection Systems Business and Results for Quarter Ended September 30, 2022 Reduces Cash Burn, Includes Seven-Year Earn-Out Provision; Quarter Revenue Expected to be Approximately $2.5 Million; Customer Sites Increase 18% YoY ORANGE, NJ,
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Appoints Joe Harris to Its Board of Directors
Appoints Joe Harris to Its Board of Directors ORANGE, NJ, September 8, 2022 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Har
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for Quarter Ended
Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months Quarter Revenue of $2.9 Million, Year-Over-Year Increase of 27%; Number of Active Customer Sites Climbs 21% Year-Over-Year ORANGE, NJ, July 6, 2022 - Nephros, Inc. (
Read more →NEPH▼ -12.8%on this news
Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Receives FDA 510(k) Clearance for HDF Assist Module The First and Only FDA-Cleared Device Available in the United States to
Receives FDA 510(k) Clearance for HDF Assist Module First and Only FDA-Cleared Device Available in the United States to Provide Hemodiafiltration Therapy to Dialysis Patients ORANGE, NJ, May 17, 2022 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results Reports Full-Year Net Revenue of $10.4 Million, a 22% Year-O
Announces Fourth Quarter and Fiscal Year 2021 Financial Results Full-Year Net Revenue of $10.4 Million, a 22% Year-Over-Year Increase and Fourth Quarter Net Revenue of $2.8 Million, an 18% Year-Over-Year Increase; Reaffirms Fiscal Year 2022 Guidance of $13.0 Million to $13.5 M
Read more →NEPHNephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022 Anticipates Record Full-Year Net Revenue of $10.4 Million, a 21% Year-Over-Year Increase and Fourth Quarter Reve
Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Record Full-Year Net Revenue of $10.4 Million, a 21% Year-Over-Year Increase and Fourth Revenue of $2.8 Million, an 18% Year-Over-Year Increase; 2022 Guidance of $13.0 Million to $13.5 Million in Annual
Read more →NEPHNephros Announces Preliminary Results for Third Quarter of 2021 Anticipates Net Revenue of $2.6 Million, a 24% Year-Over-Year Increase
Announces Preliminary Results for Third Quarter of 2021 Net Revenue of $2.6 Million, a 24% Year-Over-Year Increase ORANGE, NJ, October 8, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medica
Read more →NEPHNephros Appoints Wes Lobo to Chief Commercial Officer
Appoints Wes Lobo to Chief Commercial Officer ORANGE, NJ, September 1, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced the appointment
Read more →NEPHNephros Announces Results for Quarter Ended
Announces Results for Quarter Ended June 30, 2021 Quarter Net Revenue of $2.3 Million; 44% Year-Over-Year Increase; Strategic Acquisition of GenArraytion, Inc.; HDF Product Submitted to FDA for 510(k) Clearance ORANGE, NJ, August 5, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leadi
Read more →NEPHNephros Announces Acquisition of GenArraytion, Inc. Strategic Acquisition Accelerates Pathogen Detection Product Development
Announces Acquisition of GenArraytion, Inc. Acquisition Accelerates Pathogen Detection Product Development ORANGE, NJ, July 12, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and comm
Read more →NEPHNephros Announces Preliminary Results for Second Quarter of 2021 Anticipates Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase; Submits HDF Product to FDA for 510(k) Clearance
Announces Preliminary Results for Second Quarter of 2021 Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase; HDF Product to FDA for 510(k) Clearance ORANGE, NJ, July 8, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtrat
Read more →NEPHNephros Announces Preliminary Results for First Quarter of 2021 Anticipates Net Revenue of $2.7 Million; Highest First Quarter in Company History
Announces Preliminary Results for First Quarter of 2021 Net Revenue of $2.7 Million; Highest First Quarter in Company History ORANGE, NJ, April 5, 2021 - Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to t
Read more →NEPHNephros Reports 2020 Fourth Quarter and Full Year Financial Results Fourth Quarter Net Revenue $2.3 Million, Up 10% Sequentially Over Third Quarter Full Year Revenue $8.6 million, Down 17% Against Prior Year
Reports 2020 Fourth Quarter and Full Year Financial Results Quarter Net Revenue $2.3 Million, Up 10% Sequentially Over Third Quarter Full Year Revenue $8.6 million, Down 17% Against Prior Year ORANGE, NJ, March 1, 2021 - Nephros, Inc. (Nasdaq:NEPH), a leading water technology
Read more →NEPHNephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Qua
Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17% ORANGE, NJ, January 12, 2021 - Nephros,
Read more →NEPHNephros Appoints Dan D'Agostino as CFO and Reports Third Quarter Financial Results Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31%
Appoints Dan D'Agostino as CFO Reports Third Quarter Financial Results Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31% ORANGE, NJ, November 5, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops a
Read more →NEPHNephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock
Announces Pricing of $5 Million Registered Direct Offering of Common Stock ORANGE, NJ, October 16, 2020 - Nephros, Inc. (Nasdaq: NEPH) ("Nephros" or the "Company"), a commercial-stage company that develops and sells high performance water purification products and pathogen dete
Read more →NEPHNephros Announces Preliminary Third Quarter Revenues of $2.1 Million
Announces Preliminary Third Quarter Revenues of $2.1 Million ORANGE, NJ, October 6, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial
Read more →NEPHNephros Names Andy Astor President and Chief Executive Officer Daron Evans to Remain Senior Science Advisor and CEO of Specialty Renal Products
Names Andy Astor President and Chief Executive Officer Evans to Remain Senior Science Advisor and CEO of Specialty Renal Products ORANGE, NJ, August 14, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells water purification products and patho
Read more →NEPHNephros Reports Second Quarter Financial Results Net Revenue down 32% due to COVID-19 Interruptions
Reports Second Quarter Financial Results Revenue down 32% due to COVID-19 Interruptions ORANGE, NJ, August 5, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to t
Read more →NEPHNephros Announces Preliminary Financial Results for Second Quarter 2020 Anticipates $1.6 Million Net Revenues
Announces Preliminary Financial Results for Second Quarter 2020 $1.6 Million Net Revenues ORANGE, NJ, July 8, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to
Read more →NEPHNephros, Inc. to Hold Virtual Annual Meeting of Stockholders Executives to Present Business Overviews
Inc. to Hold Virtual Annual Meeting of Stockholders Executives to Present Business Overviews ORANGE, NJ, May 11, 2020 - Nephros, Inc. (Nasdaq: NEPH) announced today that, due to the public health concerns associated with the ongoing coronavirus outbreak and to support the heal
Read more →NEPHNephros Reports First Quarter Financial Results Product Revenue up 43% over Q1 2019
Reports First Quarter Financial Results Revenue up 43% over Q1 2019 ORANGE, NJ, May 6, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commerci
Read more →NEPHNephros Announces Preliminary Financial Results for First Quarter 2020 Anticipates $2.6 Million Net Revenues, Approximately 45% Growth Over 2019
Announces Preliminary Financial Results for First Quarter 2020 $2.6 Million Net Revenues, Approximately 45% Growth Over 2019 ORANGE, NJ, April 2, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification product
Read more →NEPHNephros Reports 2019 Fourth Quarter and Full Year Financial Results Fourth Quarter Net Revenue up 96%; Annual Net Revenue up 82% Establishes 2020 Revenue Guidance at $14.5 to $15.5 Million
Reports 2019 Fourth Quarter and Full Year Financial Results Quarter Net Revenue up 96%; Annual Net Revenue up 82% 2020 Revenue Guidance at $14.5 to $15.5 Million ORANGE, NJ, February 27, 2020 - Nephros, Inc. (Nasdaq:NEPH), a commercial stage company that develops and sells hig
Read more →NEPHNephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock
Announces Pricing of $7.5 Million Underwritten Offering of Common Stock ORANGE, NJ, January 31, 2020 - Nephros, Inc. (Nasdaq: NEPH) ("Nephros" or the "Company"), a a commercial-stage company that develops and sells high performance water purification products and pathogen detec
Read more →NEPHDear Friends and Shareholders, With the turn of the new year, we are writing to provide a comprehensive update about Nephros and our plans for the future. In the two years since our last shareholder letter, we have grown
Friends and Shareholders, the turn of the new year, we are writing to provide a comprehensive update about Nephros and our plans for the future. the two years since our last shareholder letter, we have grown revenues over 200%, redesigned our Hemodiafiltration (HDF) Assist Dev
Read more →NEPHNephros Announces Launch of PluraPath TM , a Real-Time, Portable, Water Pathogen Detection System
Announces Launch of PluraPathTM, a Real-Time, Portable, Water Pathogen Detection System ORANGE, NJ, January 9, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to
Read more →NEPHNephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019 Anticipates $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018; Fourth Quarter Year-Over-Year Revenue Growth Approx
Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019 $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018; Fourth Quarter Year-Over-Year Revenue Growth Approximately 99% ORANGE, NJ, January 6, 2020 - Nephros, Inc. (Nasdaq: NEPH), a co
Read more →NEPHNephros Reports Third Quarter Financial Results Product Revenue up 85% over Q3 2018 Reiterates Full-Year Revenue Guidance of $9.5-10 Million
Reports Third Quarter Financial Results Revenue up 85% over Q3 2018 Reiterates Full-Year Revenue Guidance of $9.5-10 Million ORANGE, NJ, November 6, 2019 - Nephros, Inc. (Nasdaq:NEPH), a commercial stage company that develops and sells high performance water purification prod
Read more →NEPHNephros Announces Preliminary Financial Results for Third Quarter 2019 Anticipates $3.1 Million Product Revenue, 85% Growth Over 2018; Increases Full-Year Revenue Guidance to $9.5-10 Million
Announces Preliminary Financial Results for Third Quarter 2019 $3.1 Million Product Revenue, 85% Growth Over 2018; Increases Full-Year Revenue Guidance to $9.5-10 Million ORANGE, NJ, October 7, 2019 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and s
Read more →NEPHNephros Announces Listing on Nasdaq Capital Market
Announces Listing on Nasdaq Capital Market ORANGE, NJ, August 13, 2019 - Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that its common sh
Read more →NEPHNephros Reports Second Quarter Financial Results Product Revenue up 88% over Q2 2018; Reiterates 2019 Full-Year Revenue Guidance
Reports Second Quarter Financial Results Revenue up 88% over Q2 2018; Reiterates 2019 Full-Year Revenue Guidance ORANGE, NJ, August 7, 2019 - Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance water purification products to the med
Read more →NEPHNephros Announces Second Quarter 2019 Financial Results Conference Call and Record Revenue of Over $1 Million in July
Announces Second Quarter 2019 Financial Results Conference Call and Record Revenue of Over $1 Million in July ORANGE, NJ, July 30, 2019 - Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical
Read more →NEPHNephros Announces Preliminary Financial Results for Second Quarter 2019 and Reverse Stock Split Anticipates $2.3 Million Net Revenue; 70% Growth Over Prior Year Reiterates Full-Year 2019 Revenue Guidance
Announces Preliminary Financial Results for Second Quarter 2019 and Reverse Stock Split $2.3 Million Net Revenue; 70% Growth Over Prior Year Reiterates Full-Year 2019 Revenue Guidance ORANGE, NJ, July 9, 2019 - Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that deve
Read more →NEPHNephros Announces $2 Million Private Placement
Announces $2 Million Private Placement ORANGE, NJ, May 16, 2019 - Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that it ha
Read more →NEPHNephros Reports First Quarter Financial Results Revenues up 80% over Q1 2018 Driven by Hospital Footprint Expansion Reiterates 2019 Guidance for Revenue Growth of 50% to 65%
Reports First Quarter Financial Results up 80% over Q1 2018 Driven by Hospital Footprint Expansion 2019 Guidance for Revenue Growth of 50% to 65% ORANGE, NJ, May 8, 2019 - Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance water pu
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Announces Preliminary Financial Results for First Quarter 2019 Anticipates $1.7 Million
Announces Preliminary Financial Results for First Quarter 2019 $1.7 Million Revenue; Year-over-Year Growth Exceeds 75% ORANGE, NJ, April 8, 2019 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device and commercial products company that develops and sells high perfor
Read more →NEPHNephros Reports 2018 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Annual Product Revenues Up 54%
Reports 2018 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Product Revenues Up 54% ORANGE, NJ, March 12, 2019 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purifi
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Appoints Alisa Lask to its Board of Directors
Appoints Alisa Lask to its Board of Directors ORANGE, NJ, February 11, 2018 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced the appointment of Alisa Lask to its B
Read more →NEPHNephros Announces Preliminary Financial Results for Fiscal Year 2018 Anticipates $5.6-5.7 Million Total Revenue; Product Revenue Growth Over 50%
Announces Preliminary Financial Results for Fiscal Year 2018 $5.6-5.7 Million Total Revenue; Product Revenue Growth Over 50% ORANGE, NJ, January 9, 2018 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid pur
Read more →NEPHNephros Announces Acquisition of Biocon Adds Growing Water Filtration Business in Food Service, Hospitality, and Industrial Markets Expands Water Filter Product Portfolio
Announces Acquisition of Biocon Growing Water Filtration Business in Food Service, Hospitality, and Industrial Markets Water Filter Product Portfolio ORANGE, NJ, January 2, 2019 - Nephros, Inc. (OTCQB: NEPH) ("Nephros"), a commercial stage company that develops and sells high
Read more →NEPHUnaudited Pro Forma Consolidated Balance Sheet of Nephros, Inc. as of
Pro Forma Consolidated Balance Sheet of Nephros, Inc. as of September 30, 2018 July 2018, Nephros, Inc. (the "Company") formed a new, wholly-owned subsidiary, Specialty Renal Products, Inc. ("SRP"), to drive the development of its 2nd generation HDF system and other products fo
Read more →NEPHNephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Announces Preliminary Financial Results for Third Quarter 2018 Anticipates 102% Year-ove
Announces Preliminary Financial Results for Third Quarter 2018 102% Year-over-Year Product Revenue Growth; $6 Million 2018 Revenue Target ORANGE, NJ, October 1, 2018 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performa
Read more →NEPHSpecialty Renal Products Announces $3 Million Series A Financing
Renal Products Announces $3 Million Series A Financing ORANGE, NJ, September 6, 2018 - Specialty Renal Products, Inc. (SRP), a private medical device company focused on the development of products for patients with renal disease, including a hemodiafiltration (HDF) system for t
Read more →NEPHNephros Appoints Oliver Spandow to its Board of Directors Seasoned Executive Adds Significant Operational and M&A Expertise
Appoints Oliver Spandow to its Board of Directors Executive Adds Significant Operational and M&A Expertise ORANGE, NJ, August 13, 2018 - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafil
Read more →NEPHNephros Announces Preliminary Financial Results for Second Quarter 2018 Anticipates 57% Year-over-Year Revenue Growth; Establishes Specialty Renal Products Subsidiary
Announces Preliminary Financial Results for Second Quarter 2018 57% Year-over-Year Revenue Growth; Specialty Renal Products Subsidiary ORANGE, NJ, July 9, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and s
Read more →NEPHNephros Announces Preliminary Financial Results for First Quarter 2018 Anticipates 39% Year-over-Year Product Revenue Growth; Reiterates $6 million 2018 Revenue Target
Announces Preliminary Financial Results for First Quarter 2018 Anticipates 39% Year-over-Year Product Revenue Reiterates $6 million 2018 Revenue Target ORANGE, NJ, April 16, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company
Read more →NEPHNephros Announces $2.9 Million Private Placement
Announces $2.9 Million Private Placement ORANGE, NJ, April 11, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltr
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Reports 2017 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Annual R
Reports 2017 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Revenues Up 65% and Cash Flow from Operations Approaches Breakeven ORANGE, NJ, February 26, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device co
Read more →NEPHNephros, Inc. 380 Lackawanna Pl, South Orange, NJ 07079 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Announces Preliminary Financial Results for Fourth Quarter 2017 Anticipates Over 80% Year-
Announces Preliminary Financial Results for Fourth Quarter 2017 Over 80% Year-over-Year Product Revenue Growth for the Quarter ORANGE, NJ, January 4, 2018 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells hi
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Provides Corporate Update and Announces Preliminary Third Quarter 2017 Revenue Anticipates Over 90
Provides Corporate Update and Announces Preliminary Third Quarter 2017 Revenue Over 90% Year-over-Year Revenue Growth in the Third Quarter and Cash Flow Breakeven around Year-End EDGE, NJ, October 16, 2017 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH) (the "Company"), a
Read more →NEPHDear Friends and Shareholders, This is an exciting time for Nephros. Demand for our products is increasing, revenue and growth rates are expanding, and we anticipate continued progress. At the same time, our stock price
Friends and Shareholders, is an exciting time for Nephros. Demand for our products is increasing, revenue and growth rates are expanding, and we anticipate continued progress. At the same time, our stock price has been stagnant, which is difficult to reconcile with our recent o
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Provides Corporate Update and Second Quarter 2017 Revenue Guidance Anticipates 70% Year-over-Year
Provides Corporate Update and Second Quarter 2017 Revenue Guidance 70% Year-over-Year Revenue Growth in the Second Quarter and Cash Flow Breakeven around Year-End EDGE, NJ, July 10, 2017 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage m
Read more →NEPHNephros Announces $ 1.2 Million Private Placement
Announces $1.2 Million Private Placement EDGE, NJ, March 17, 2017 / Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration syst
Read more →NEPHNephros Announces Appointment of Andrew Astor as Chief Financial Officer Technology Industry Veteran Andrew Astor Hired to Support Growth and Business Momentum
Announces Appointment of Andrew Astor as Chief Financial Officer Industry Veteran Andrew Astor Hired to Support Growth and Business Momentum EDGE, NJ, February 14, 2017 /Market Wire/ - Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that d
Read more →NEPHNephros Provides Corporate Update and Fourth Quarter 2016 Revenue Guidance -Projects Positive Cash Flow by Mid 2017
Provides Corporate Update and Fourth Quarter 2016 Revenue Guidance Positive Cash Flow by Mid 2017- EDGE, NJ, January 24, 2017 /PR Newswire-FirstCall/ - Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performanc
Read more →NEPHNephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
Receives FDA 510(k) Clearance of S100 Point of Use Filter EDGE, NJ, April 14, 2016- Nephros, Inc. (OTCQB:NEPH), (the "Company") a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodi
Read more →NEPHDEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration New Jersey District Office Central Region Waterview Corporate Center 10 Waterview Blvd. 3 rd Floor Parsippany, New Jersey 07054 Telephone: (973) 331-49
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration New Jersey District Office Central Region Waterview Corporate Center 10 Waterview Blvd. 3 rd Floor Parsippany, New Jersey 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 UNITED PARCEL SERVICE Daron G. Eva
Read more →NEPHNephros Reports Preliminary 2015 Revenue and Provides Update
Reports Preliminary 2015 Revenue and Provides Update EDGE, NJ, February 1, 2016 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-l
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Announces Funding from Warrant Exercise by Wexford Capital and Plan to Temporarily Reduce Exercise
Nephros Announces Funding from Warrant Exercise by Wexford Capital and Plan to Temporarily Reduce Exercise Price for All Outstanding Warrants RIVER EDGE, NJ, September 30, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company tha
Read more →NEPHNephros Appoints Moshe Pinto to its Board of Directors
Nephros Appoints Moshe Pinto to its Board of Directors RIVER EDGE, NJ, August 17, 2015 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-
Read more →NEPHNephros, Inc.
Nephros, Inc. Enters Into Purchase Agreement with Lincoln Park Capital Fund, LLC RIVER EDGE, N.J., July 27, 2015 - Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line m
Read more →NEPHAttention: Mr.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration New Jersey District Office Central Region Waterview Corporate Center 10 Waterview Blvd. 3 rd Floor Parsippany, New Jersey 07054 Telephone: (973) 331- 4900 FAX: (973) 331- 4969 VIA UNITED PARCEL SERVICE Atten
Read more →NEPHNephros Appoints Daron Evans as President and Chief Executive Officer and Lawrence Centella as Chairman of the Board of Directors RIVER EDGE, N.J. Nephros, Inc. ( NEPH ), a commercial stage medical device company that de
Nephros Appoints Daron Evans as President and Chief Executive Officer and Lawrence Centella as Chairman of the Board of Directors Inc. (NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com PRESS RELEASE Nephros Appoints Paul A. Mieyal as Acting Chief Executive Officer and Daron Evans as Chairman of the Board
Nephros Appoints Paul A. Mieyal as Acting Chief Executive Officer and Daron Evans as Chairman of the Board of Directors RIVER EDGE, N.J.--(BUSINESS WIRE) January 7, 2015 -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high perfo
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Announces Successful Completion of $3 million Rights Offering
Nephros Announces Successful Completion of $3 million Rights Offering RIVER EDGE, NJ, December 18, 2014 -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilut
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Receives 510(k) Clearance for DSU-H and SSU-H Ultrafilters
Nephros Receives 510(k) Clearance for DSU-H and SSU-H Ultrafilters RIVER EDGE, NJ, October 28, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Completes Bridge Financing
Nephros Completes Bridge Financing RIVER EDGE, NJ, September 3, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafi
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Appoints Matthew S. Rosenberg to Board of Directors
Nephros Appoints Matthew S. Rosenberg to Board of Directors RIVER EDGE, NJ, May 19, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mi
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Announces Completion of Rights Offering
Nephros Announces Completion of Rights Offering RIVER EDGE, NJ, March 24, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros and Bellco Extend and Expand License Agreement
Nephros and Bellco Extend and Expand License Agreement RIVER EDGE, NJ, February 25, 2014 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and Bellco S.r.l.
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Appoints Daron Evans to Board of Directors
Nephros Appoints Daron Evans to Board of Directors RIVER EDGE, NJ, November 29, 2013 /PR Newswire-FirstCall/ - Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announc
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing RIVER EDGE, NJ, November 14, 2013 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Reports Third Quarter 2012 Financial Results
Nephros Reports Third Quarter 2012 Financial Results RIVER EDGE, NJ, November 8, 2012 /PR Newswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announ
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Receives 510(k) Clearance for Hemodiafiltration System
Nephros Receives 510(k) Clearance for Hemodiafiltration System RIVER EDGE, NJ - April 30, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications and advanced water purification soluti
Read more →NEPHNephros, Inc. 41 Grand Ave River Edge, NJ 07661 T: 201. 343. 5202 F: 201. 343. 5207 www.nephros.com Nephros Announces Strategic License and Supply Agreement with Medica S.p.A for Ultrafiltration Products
Nephros Announces Strategic License and Supply Agreement with Medica S.p.A for Ultrafiltration Products RIVER EDGE, NJ - April 23, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic application
Read more →NEPHNephros, Inc. Announces Date of its 2012 Annual Meeting of Stockholders
Nephros, Inc. Announces Date of its 2012 Annual Meeting of Stockholders RIVER EDGE, NJ - February 10, 2012 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and wa
Read more →NEPHNephros, Inc. Post-Effective Amendment No. 2 to Registration Statement Declared Effective
Nephros, Inc. Post-Effective Amendment No. 2 to Registration Statement Declared Effective RIVER EDGE, NJ - October 18, 2011 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection c
Read more →NEPHNephros Files 510(k) Application for Hemodiafiltration System
Nephros Files 510(k) Application for Hemodiafiltration System RIVER EDGE, NJ - August 11, 2011 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purificatio
Read more →NEPHNephros Provides Corporate Update
Nephros Provides Corporate Update RIVER EDGE, NJ - July 26, 2011 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today provided an update on
Read more →NEPHNephros Receives 510k Approval to Market Additional Ultrafiltration Products
Nephros Receives 510k Approval to Market Additional Ultrafiltration Products RIVER EDGE, NJ - July 21, 2011 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and wate
Read more →NEPHNephros and Bellco S.r.l. Announce License Agreement for Mid-Dilution Dialysis Products RIVER EDGE, N.J. and MIRANDOLA, ITALY
Nephros and Bellco S.r.l. Announce License Agreement for Mid-Dilution Dialysis Products RIVER EDGE, N.J. and MIRANDOLA, ITALY, June 27, 2011 /PRNewswire/ - Nephros, Inc. (OTC Bulletin Board:NEPH.OB - News), a medical device company developing and marketing filtration products fo
Read more →NEPHNephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions
Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions RIVER EDGE, N.J., March 10, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH.ob - News), a medical device company developing and marketing filtration pro
Read more →NEPHNephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions RIVER EDGE, N.J. , Mar . 4, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH. OB - News ), a m
Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions RIVER EDGE, N.J., Mar. 4, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH.OB - News), a medical device company developing and marketing filtration produ
Read more →NEPHNephros Extends Rights Offering
Nephros Extends Rights Offering RIVER EDGE, NJ, February 28, 2011 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purificati
Read more →NEPHNephros Rights Offering Registration Statement Declared Effective
Rights Offering Registration Statement Declared Effective EDGE, NJ, January 31, 2011 /PRNewswire-FirstCall/ - Nephros, Inc. (OTC Bulletin Board:NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control,
Read more →NEPHE xhibit 99.1 Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
Completes Bridge Financing and Announces Stockholder Rights EDGE, NJ, October 1, 2010 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control
Read more →NEPHNephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration EDGE, N.J., July 7, 2010 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications,
Read more →NEPHNephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems EDGE, N.J., July 6, 2010 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board:NEPH - News), a medical device company developing and marketing filtration pro
Read more →NEPHNephros Reports 2010 First Quarter Financial Results RIVER EDGE, NJ--(PRNewswire)
Reports 2010 First Quarter Financial Results EDGE, NJ--(PRNewswire)-May 13, 2010 -- Nephros, Inc. (OTC:NEPH.OB - News) announced today financial results for the three months ended March 31, remainder of 2010, the company's primary focus is to obtain a formal response to our p
Read more →NEPHNephros Signs Development Agreement with
Signs Development Agreement with STERIS EDGE, NJ - March 23, 2010 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is
Read more →NEPHNephros Awarded $2 Million Contract Expansion by the Office of Naval Research
Awarded $2 Million Contract Expansion by the Office of Naval August 31, 2009 - Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today report
Read more →NEPHNephros, Inc. Completes $1.25 Million Private Placement RIVER EDGE, N.J., July 30/PRNewswire-FirstCall/ - Nephros, Inc. (OTC Bulletin Board: NEPH - News), a medical device company developing and marketing filtration prod
Inc. Completes $1.25 Million Private Placement EDGE, N.J., July 30/PRNewswire-FirstCall/ - Nephros, Inc. (OTC Bulletin Board: NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purific
Read more →NEPHNephros Common Stock Now Quoted in Pink Sheets
Nephros Common Stock Now Quoted in Pink January 26, 2009 --- Nephros, Inc. (Pink Sheets: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that its common stock
Read more →NEPHNephros Receives Notice of Intention to Delist from
Receives Notice of Intention to Delist from AMEX RIVER EDGE, NJ- January 14, 2009 --- Nephros, Inc. (AMEX: NEP), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that
Read more →NEPHNephros Provides Corporate Update Thursday
Provides Corporate Update NY--(PR NEWSWIRE)--November 20, 2008 -- Nephros, Inc. (AMEX:NEP - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today provided an update on its op
Read more →NEPHUnassociated Document Nephros Reports Third Quarter 2008 Financial Results
Reports Third Quarter 2008 Financial Results YORK, NY-November 14, 2008 Nephros, Inc. (AMEX: announced today unaudited financial results for the three and nine month periods ended September 30, 2008. Performance for the Quarter Ended September 30, 2008: quarter ended Septem
Read more →NEPHNEPHROS RECEIVES NON-COMPLIANCE
RECEIVES NON-COMPLIANCE NOTIFICATION FROM AMEX - September 18, 2008 - Nephros, Inc. (AMEX:NEP) today announced that the Company has received notice from the staff of the American Stock Exchange (AMEX) indicating that the Company is not in compliance with certain conditions of
Read more →NEPHFor more information on Nephros please visit the Company's website, www.nephros.com. Forward-Looking Statements This news release contains certain " forward-looking statements " within the meaning of the Private Securiti
Appoints Ernest A. Elgin III as President and Chief Executive NY - September 17, 2008 - Nephros, Inc. (AMEX:NEP - News) today announced that, effective September 15, 2008, Ernest A. Elgin III has been appointed President and Chief Executive Officer. joins the company from Nov
Read more →NEPHNephros Reports Second Quarter 2008 Financial Results
Reports Second Quarter 2008 Financial Results YORK, NY-August 14, 2008 Nephros, Inc. (AMEX: announced today financial results for the three and six month periods ended quarter ended June 30, 2008, Nephros reported net product revenues of $253,000, attributable to sales of it
Read more →NEPHNephros Reports 2008 First Quarter Financial Results Thursday
Reports 2008 First Quarter Financial Results NY -- May 15, 2008 -- Nephros, Inc. (AMEX:NEP - News) announced today financial results for the three month period ended March 31, 2008. first quarter of 2008 marked another milestone for Nephros on the path toward U.S. approval of
Read more →NEPHNephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 Company Management to discuss the benefits of Hemodiafiltration therapy and Quality of Life for En
to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, Management to discuss the benefits of Hemodiafiltration therapy and Quality Life for End-Stage Renal Disease Patients NY - May 13, 2008. Nephros, Inc., a medical device company developing and marketing p
Read more →NEPHNephros Appoints Gerald J. Kochanski as Chief Financial Officer NEW YORK, NY -- Nephros, Inc. (Amex: NEP - News) today announced that, effective
Appoints Gerald J. Kochanski as Chief Financial Officer NY -- Nephros, Inc. (Amex: NEP - News) today announced that, effective April 2008, Gerald J. Kochanski has been appointed Chief Financial Kochanski joins the company from Lordi Consulting LLC, where he has served Directo
Read more →NEPHNephros, Inc. Substantially Increases Stockholders' Equity and Expects to Regain Compliance with the American Stock Exchange Continued Listing
Substantially Increases with the American Stock Exchange Continued Listing YORK, January 16, 2008 - Nephros, Inc. (AMEX: NEP) announced today that, as a result of the issuance of notes in the third quarter of 2007, representing an aggregate principal amount of $18 million, an
Read more →NEPHNephros Appoints James S. Scibetta to Board of Directors
Appoints James S. Scibetta to Board of Directors YORK, NY - November 20, 2007 - Nephros, Inc. (AMEX: NEP), a medical device company focused on developing advanced filtration products for ESRD therapy and water purification, announced today that Mr. James S. Scibetta was appoi
Read more →NEPHNephros Reports Third Quarter 2007 Financial Results
Reports Third Quarter 2007 Financial Results YORK, NY-November 13, 2007 - Nephros, Inc. (AMEX: NEP) announced today financial results for the three and nine month periods ended third quarter of 2007 has been an exciting period for Nephros," said Norman J. Barta, Chairman and
Read more →NEPHNephros Initiates Pivotal U.S. Trial for OLpur H2H Hemodiafiltration Module and OLpur MD 220 Hemodiafilter
Initiates Pivotal U.S. Trial for OLpur H2H Hemodiafiltration Module and OLpur MD 220 Hemodiafilter YORK, NY - October 16, 2007 (AMEX:NEP) today announced that the Company has begun the pivotal human clinical trial for its OLpur H2H Hemodiafiltration Module and OLpur MD 220 H
Read more →NEPHNephros Receives Non-Compliance Notification from Amex New York, NY
Receives Non-Compliance Notification from Amex York, NY----October 3, 2007 --- On September 27, 2007, Nephros, Inc. (NEP:AMEX) received a warning letter from the American Stock Exchange ("the AMEX") stating that the staff of the Amex Listing Qualifications Department has dete
Read more →NEPHNephros Raises $12.7 Million in New Financing Company to Use Proceeds for Clinical Trials, Product Marketing and Working Capital
Raises $12.7 Million in New Financing to Use Proceeds for Clinical Trials, Product Marketing and Working YORK, September 25, 2007 - Nephros, Inc. (AMEX: NEP) announced today that it has entered into several subscription agreements whereby Lambda Investors LLC, GPC 76 LLC, Lew
Read more →NEPHNephros Reports Second Quarter 2007 Financial Results Revenues Increase 15%, Net Loss is Reduced NEW YORK, NY-August [13] , 2007 - Nephros, Inc. ( AMEX: NEP ) announced today financial results for the three and six month
Reports Second Quarter 2007 Financial Results Increase 15%, Net Loss is Reduced 2007 - Nephros, Inc. (AMEX: NEP) announced today financial results for the three and six month periods ended June 30, quarter ended June 30, 2007, Nephros reported net product revenues of $348,000
Read more →NEPHNephros Names New Independent Auditing Firm
Names New Independent Auditing Firm YORK, NY - July 20, 2007 - Nephros, Inc. (AMEX:NEP) today announced that the Audit Committee of the Board of Directors of the Company engaged Rothstein Kass & Company, P.C. as the Company's new independent registered public accounting firm.
Read more →NEPHNephros Reports Departure of Director
Reports Departure of Director YORK, NY - May 23, 2007 - Nephros, Inc. (AMEX:NEP) today announced that, on May 22, 2007, Dr. Bernard Salick submitted his resignation from the Company's Board of Directors (the "Board") effective immediately to pursue other business interests. D
Read more →NEPHNEPHROS, INC. 2007 Annual Stockholders Meeting
Forward Looking Statements presentation contains certain "forward-looking statements" within the meaning the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy and intended use Nephros' technologies, the
Read more →NEPHNephros Reports First Quarter 2007 Financial Results Revenues Increase 70%, Net Loss is Reduced
Reports First Quarter 2007 Financial Results Increase 70%, Net Loss is Reduced May 15, 2007 - Nephros, Inc. (AMEX: NEP) announced today financial results the three months ended March 31, 2007. quarter ended March 31, 2007, Nephros reported net revenue of $296,000, attributab
Read more →NEPHNephros Provides Information Regarding Auditor's Going Concern Report and Fiscal 2006 Results
Provides Information Regarding Auditor's Going Concern Report and May 3, 2007 - Nephros, Inc. (AMEX: NEP) announced today that its consolidated financial statements for the year ended December 31, 2006, which were included in its Annual Report on Form 10-KSB filed with the Sec
Read more →NEPHNephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application Nephros MD and H 2 H Technologies Targeted to Begin Clinical Trials in First Quarter 2007 New York, NY
Receives Conditional Approval the FDA of Investigational Device Technologies Targeted to Begin Clinical Trials in First Quarter NY--January 29, 2007 -- Nephros, Inc. (AMEX:NEP) reported that the Company received conditional approval for its Investigational Device Exemption (
Read more →NEPHAmerican Stock Exchange Will Continue Nephros's Listing
Stock Exchange Will Continue Nephros's Listing YORK -November 20, 2006 - Nephros, Inc. (AMEX:NEP) announced that the staff of the American Stock Exchange (AMEX) has reviewed Company's plan of compliance to meet the AMEX's continued listing standards and will continue the Comp
Read more →NEPHNephros Receives Extension to Submit AMEX Plan of Compliance
Receives Extension to Submit AMEX Plan of Compliance YORK -August 17, 2006 - Nephros, Inc. (AMEX:NEP) announced that the American Stock Exchange (AMEX) has granted the Company a week extension, until August 24, 2006, to submit a plan of compliance advising the AMEX of the act
Read more →NEPHNorman Barta, CEO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Selects Director William Fox to Serve as Executive Chairman
Russell / Todd Fromer 212-896-1250 / 212-896-1215 Selects Director William Fox to Serve as Executive Chairman YORK, August 4, 2006 - Nephros, Inc. (AMEX: NEP), announced today the appointment of William J. Fox, CPA, as Executive Chairman of the Board. Mr. Fox has served as a
Read more →NEPHNephros Receives Non-compliance Notification from
Receives Non-compliance Notification from AMEX YORK - July 21, 2006 - Nephros, Inc. (AMEX:NEP) announced that the Company has received notice from the American Stock Exchange (AMEX) that AMEX has determined that the Company is not in compliance with certain conditions of the
Read more →NEPHNEPHROS, INC. 2006 Annual Stockholders Meeting
Annual Stockholders Meeting Inc. Cautionary Statements presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy and intended
Read more →NEPHNephros Completes $5 Million Private Placement -Company to Use Proceeds for Product Development, Marketing and Working Capital- New York, N.Y. - Nephros, Inc. (AMEX:NEP) today announced that the Com
Completes $5 Million Private Placement to Use Proceeds for Product Development, Marketing and Working York, N.Y. - Nephros, Inc. (AMEX:NEP) today announced that the Company has entered into subscription agreements with several investors for the sale of an aggregate of $5 mill
Read more →NEPHNephros Appoints Mark W. Lerner Chief Financial Officer New York, N.Y.
Appoints Mark W. Lerner Chief Financial Officer York, N.Y. - March 8, 2006 - Nephros, Inc. (AMEX:NEP) today announced that the Board of Directors appointed Mark W. Lerner to the post of Chief Financial Officer, effective March 6, 2006. Lerner served as a consultant to Pipelin
Read more →NEPHNorman Barta, CEO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Announces First Order from Major U.S. Hospital for Proprietary Water
Russell / Todd Fromer 212-781-5113 212-896-1250 Announces First Order from Major U.S. Hospital for Proprietary Water Filtration Nephros enters the burgeoning water purification sector with a robust filtration solution. Nephros initially targets medical institutions with its n
Read more →NEPHGRAPHIC OMITTED][GRAPHIC OMITTED] Contact: Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Reports Third Quarter 2005 Financial Results
[GRAPHIC OMITTED][GRAPHIC OMITTED] Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Reports Third Quarter 2005 Financial Results NEW YORK, November 14, 2005 - Nephros, Inc. (AMEX: NEP) announced t
Read more →NEPHNEPHROS FOR IMMEDIATE RELEASE Contacts: Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 NEPHROS, INC. TO PRESENT AT THE C.E. UNTERBERG
Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 NEPHROS, INC. TO PRESENT AT THE C.E. UNTERBERG TOWBIN EMERGING GROWTH LIFE SCIENCES CONFERENCE ON OCTOBER 26TH NEW YORK, October 19, 2005 -- Nephros, Inc.
Read more →NEPHNEPHROS Contact: Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Reports Second Quarter 2005 Financial Results
Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Reports Second Quarter 2005 Financial Results NEW YORK, August 15, 2005 - Nephros, Inc. (AMEX: NEP) announced today financial results for the three
Read more →NEPHSlide 1] NEPHROS, INC. 2005 Annual Stockholders Meeting
2005 Annual Stockholders Meeting Forward Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy an
Read more →NEPHMarc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 grussell@kcsa.com / tfromer@kcsa.com ------------------------------------ Nephros Receives
Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 grussell@kcsa.com / tfromer@kcsa.com ------------------------------------ Nephros Receives FDA Approval For its OLpur(TM) HD190 High Flux Filter NEW YORK
Read more →NEPHGarth Russell / Todd Fromer 212-896-1250 / 212-896-1215 grussell@kcsa.com / tfromer@kcsa.com ----------------- ------------------- NEPHROS, INC. INITIATES SUPPLEMENTAL EUROPEAN CLINICAL TRI
Garth Russell / Todd Fromer 212-896-1250 / 212-896-1215 grussell@kcsa.com / tfromer@kcsa.com ----------------- ------------------- NEPHROS, INC. INITIATES SUPPLEMENTAL EUROPEAN CLINICAL TRIALS FOR OLPUR(TM) NEW YORK, May 26, 2005 -- Nephros, Inc. (AMEX: NEP), announced today
Read more →NEPHGRAPHIC OMITTED][GRAPHIC OMITTED] Contact: Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 FOR IMMEDIATE RELEASE CORRECTING and REPLACING Nephros Re
[GRAPHIC OMITTED][GRAPHIC OMITTED] Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 CORRECTING and REPLACING Nephros Reports First Quarter 2005 Financial Results NEW YORK--(BUSINESS WIRE)--May 16, 2005--I
Read more →NEPHGRAPHIC OMITTED][GRAPHIC OMITTED] For Immediate Release Contact: Marc Pannoff Todd Fromer or Garth Russell Chief Financial Officer KCSA Worldwide Nephros, Inc. 212-896-1215 / 212-896-1250 Tel: 212-781-5113 tfromer@kcsa.c
[GRAPHIC OMITTED][GRAPHIC OMITTED] Marc Pannoff Todd Fromer or Garth Russell Chief Financial Officer KCSA Worldwide Nephros, Inc. 212-896-1215 / 212-896-1250 Tel: 212-781-5113 tfromer@kcsa.com / grussell@kcsa.com ---------------- ----------------- Nephros Inc. Appoints Bern
Read more →NEPHGRAPHIC OMITTED] Contact: Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 FOR IMMEDIATE RELEASE Nephros Reports Fourth Quarter and Year End Financia
Marc Panoff, CFO Garth Russell / Todd Fromer Nephros, Inc. KCSA Worldwide Tel: 212-781-5113 212-896-1250 / 212-896-1215 Nephros Reports Fourth Quarter and Year End Financial Results NEW YORK, March 31, 2005 - Nephros, Inc. (AMEX: NEP) announced today financial results for th
Read more →NEPHGRAPHIC OMITTED][GRAPHIC OMITTED] Press Release Nephros Announces 510(k) Filing with FDA For its OLpur(TM) HD190 High Flux Filter
[GRAPHIC OMITTED][GRAPHIC OMITTED] Nephros Announces 510(k) Filing with FDA For its OLpur(TM) HD190 High Flux Filter NEW YORK, March 14, 2005 -- Nephros, Inc. (AMEX: NEP), announced today that it has provided a 510(k) submission for its OLpur(TM) HD190 to the United States F
Read more →NEPHNEPHROS Contact: Marc Panoff, CFO Nephros, Inc. Tel: 212-781-5113 FOR IMMEDIATE RELEASE NEPHROS ENTERS INTO HEMODIAFILTER MANUFACTURING AND DISTRIBUTION RIGHTS AGREEMENT WITH ASAHI KASEI MEDICAL New York
NEPHROS ENTERS INTO HEMODIAFILTER MANUFACTURING AND DISTRIBUTION RIGHTS AGREEMENT WITH ASAHI KASEI MEDICAL New York--- March 2, 2005--Nephros, Inc. (AMEX: NEP) today announced it has entered into an agreement with Asahi Kasei Medical Co., Ltd., a business unit of Asahi Kasei
Read more →NEPHMarc Panoff, CFO Nephros, Inc. Tel: 212-781-5113 FOR IMMEDIATE RELEASE Nephros, Inc. Reports Third Quarter 2004 Financial Results New York
Nephros, Inc. Reports Third Quarter 2004 Financial Results New York -November 16, 2004 - Nephros, Inc. (AMEX: NEP) announced today financial results for the third quarter and nine months ended September 30, Nephros reported net revenue of $46,379 for the three months ended Sep
Read more →Competitive Position
How NEPH ranks across every disease it competes inCompetitive Position is a premium feature
See how NEPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial